The non-canonical effect of tyrosine kinase inhibitors for the treatment of malignant tumors on gene expression
https://doi.org/10.25557/2073-7998.2021.12.34-39
Abstract
Targeted drugs for the treatment of oncological diseases, in particular, the inhibitors of Sunitinib and Sorafenib, are widely used in oncological practice and the study of the peculiarities of their application is very relevant. On the models of cultured cancer cells in vitro it was shown that kinase inhibitors are able to strengthen the expression of tumor progression genes (SNAI1, SNAI2, CD44, CDH1, CLDN1) associated with the epithelial-mesenchymal transition (EMT). The activation of such genes is shown under the action of low doses of tyrosine kinase inhibitors - Sunitinib and Sorafenib. The activation of the studied genes was different in different cultures and depended on the applied drug. It was assumed that due to the local uneven distribution of drugs in tissues of the tumor, kinase inhibitors may be one of the reasons for activating the expression of genes associated with the epithelial- mesenchymal transition, and thus contribute to its progression.
About the Authors
A. Yu. Kuzevanova
Research Centre for Medical Genetic
Russian Federation
Russian Federation
A. V. Karpukhin
Research Centre for Medical Genetic
Russian Federation
Russian Federation
A. A. Alimov
Research Centre for Medical Genetic
Russian Federation
Russian Federation
References
1. Mahvi D.A., Liu R., Grinstaff M.W., Colson Y.L., Raut C.P. Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA Cancer J Clin. 2018;68(6):488-505. doi:10.3322/caac.21498
2. Huang L., Jiang S., Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol. 2020;13(1):143. doi:10.1186/s13045-020-00977-0
3. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6(9):734-745. doi:10.1038/nrd2380
4. López de Andrés J., Griñán-Lisón C., Jiménez G., Marchal J.A. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol. 2020;13(1):136. doi:10.1186/s13045-020-00966-3
5. Zhu L., Jiang M., Wang H., et al. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med. 2021;9(16):1351. doi:10.21037/atm-21-1948
6. Yang J., Antin.P, Berx G., et al. Guidelines and definitions for research on epithelial-mesenchymal transition [published correction appears in Nat Rev Mol Cell Biol. 2021 Dec;22(12):834]. Nat Rev Mol Cell Biol. 2020;21(6):341-352. doi:10.1038/s41580-020-0237-9
7. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178-196. doi:10.1038/nrm3758
8. Hwang H.S., Go H., Park J.M., et al. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. Lab Invest. 2019;99(5):659-670. doi:10.1038/s41374-019-0188-y
9. Hwang H.S., Go H., Park J.M., et al. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. Lab Invest. 2019;99(5):659-670. doi:10.1038/s41374-019-0188-y
Review
For citations:
Kuzevanova A.Yu., Karpukhin A.V., Alimov A.A. The non-canonical effect of tyrosine kinase inhibitors for the treatment of malignant tumors on gene expression. Medical Genetics. 2021;20(12):34-39. (In Russ.) https://doi.org/10.25557/2073-7998.2021.12.34-39
Views:
326
Email this article 